Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions

ASH 2019

Published: 7 Dec 2019

Views: 1069

Rating:

Save

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

Dr Yu Hu presents data from a study looking at bispecific CAR-T Cell therapy in patients with multiple myeloma during a press conference at ASH 2019.

The study evaluated the sustainability of remissions in this hard to treat multiple myeloma.

Read more about the study here.

Watch our interview with Dr Yu Hu here.

Related Videos

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

Dr Alexandros Rampotas - UCL Cancer Institute, London, United Kingdom

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms ( Dr Alexandros Rampotas - UCL Cancer Institute, London, United Kingdom )

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

$Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )$

More from ecancer